Cenobamate, sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults.\u00a0Cenobamate was approved for medical use in the United States in November 2019 and placed in Schedule V of the Controlled Substances Act in March 2020. Cenobamate was approved for medical use in the European Union in March 2021 and approved for use in Canada in June 2023.<\/p>\n
If XCOPRI (cenobamate tablets)<\/strong>\u00a0are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong><\/em> NEWS \/ UPDATES<\/strong><\/p>\n Xcopri is FDA-approved\u00a0to treat partial-onset seizures (also called focal seizures) in adults. Xcopri belongs to a group of drugs called anti-epileptic drugs (AEDs), also known as anticonvulsants. Xcopri may be prescribed by itself or in combination with other drugs, such as other AEDs.<\/p>\n Source Details: Patient Information<\/a><\/p>\n IPN, New Delhi can facilitate patient to import of “XCOPRI (cenobamate tablets)”<\/strong> in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please\u00a0email IPN healthcare Support Team <\/a>for cenobamate tablets<\/strong>\u00a0price list or cost in India. on Mr. Tarun:- +91 9891 296 838 \/ Mr. Neeraj:- +91 9811 747 774.<\/strong><\/em><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n\n
XCOPRI (cenobamate tablets), for oral use, Initial U.S. Approval: XXXX<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n XCOPRI<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n cenobamate<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n Tablets: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n \u00a0SK Life<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n